FENC Stock Analysis: Buy, Sell, or Hold?
FENC - Fennec Pharmaceuticals Inc. Common Stock
$10.69
-0.01 (-0.09%)
▼
5d:
-2.99%
30d:
+16.96%
90d:
+66.51%
HOLD
MODERATE Confidence
Analysis Updated: Jul 6, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When FENC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: FENC trades at premium valuation expecting 5.2% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: FENC trades at premium valuation expecting 5.2% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$17.85
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$11.08
3.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: FENC is currently trading at $10.69, which is considered extended relative to its 30-day fair value range of $8.90 to $10.50. From a valuation perspective, the stock is trading at a premium (Forward PE: 12.0) compared to its historical average (10.3). At these levels, the market is pricing in 5.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, FENC is showing sideways momentum. The price is approaching resistance at $10.28. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: FENC has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $15.67 (+46.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, FENC is showing sideways momentum. The price is approaching resistance at $10.28. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: FENC has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $15.67 (+46.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.90 -
$10.50
Company Quality Score
64/100
(BUY)
Options IV Signal
100th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
49.2%
All Signals
- BEARISH: Price extended above range
- BEARISH: Options expensive (IV 100th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 46.6% below Wall St target ($15.67)
- NEUTRAL: Trading at premium valuation - market expects 5.2% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$8.90 -
$10.50
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$2.48
(23.2%)
Support & Resistance Levels
Support Level
$8.57
Resistance Level
$10.28
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.01
Wall Street Target
$15.67
(+46.6%)
Revenue Growth (YoY)
72.6%
Profit Margin
-16.4%
Valuation Premium vs History
+5.2% premium
PE vs Historical
12.0 vs 10.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.2%
(market-implied from PE analysis)
1-Year Target
$11.25
(+5%)
2-Year Target
$11.83
(+11%)
3-Year Target
$12.45
(+16%)
3-Yr Target (if PE normalizes)
(PE: 12→10)
PE COMPRESSION
$10.67
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 200.7%)
$65.42
(+512%)
Base:
(SPY PE: 12.0, Growth: 200.7%)
$36.08
(+238%)
Bear:
(PE: 10.2, Growth: 200.7%)
$30.67
(+187%)
Share & Embed Analysis
Last updated: July 07, 2026 5:22 AM ET
Data refreshes hourly during market hours. Next update: 6:22 AM
Data refreshes hourly during market hours. Next update: 6:22 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FENC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Rosty Raykov
SELL
10946 shares
2026-04-01
Rosty Raykov
SELL
10349 shares
2026-02-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 61 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 52 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 56 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
